PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. As the world of artificial intelligence continues to evolve, a New Jersey biotech company is taking AI capabilities to the next level. After decades of working with AI-driven phenotypic platforms in an attempt to develop drugs for mental illness, PsychoGenics has had a breakthrough with one compound that aims to treat schizophrenia. PsychoGenics president and CEO Emer Leahy spoke to Fox News Digital in a recent on-camera interview, explaining that she and her team are closer than ever to developing what she said is the first-ever AI-discovered drug.